Despite the abundance of approvals and launches of novel therapies in the oncology...
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
February’s top news stories
Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.
January’s top news stories
Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
September’s top news stories
Emerald Health Pharmaceuticals (EHP) started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and scleroderma, and Ra Pharmaceuticals reported positive data from the Phase lb trial examining the pharmacokinetic (PK) of zilucoplan (RA101495 SC) to treat patients with renal impairment. Drugdevelopment-technology.com wraps up the key news stories from September 2018.
Why are novel therapies for glioblastoma patients not gaining approvals?
Despite the abundance of approvals and launches of novel therapies in the oncology space, glioblastoma multiforme (GBM), a solid tumor type, has had no new drugs to market since the approval of Genentech’s Avastin (bevacizumab) in 2009.
August’s top news stories
Gradalis started a Phase lll clinical trial of Vigil in combination with irinotecan and temozolomide for the treatment of patients with Ewing’s sarcoma, and Impel NeuroPharma dosed the first subject in the Phase l Safety and Tolerability of Intranasal POD-olanzapine (SNAP 101) trial of INP105. Drugdevelopment-technology.com wraps up the key news stories from August 2018.
July’s top news stories
The Kyoto University’s Centre for iPS Cell Research and Application (CiRA) in Japan is to start two clinical trials that will evaluate human induced pluripotent stem cells (iPS) to treat Parkinson’s disease, and Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), along with Parkinson’s UK, announced that the European Medicines Agency (EMA) issued a positive qualification opinion on biomarker as a tool to boost clinical trials on Parkinson’s. Drugdevelopment-technology.com wraps up the key news stories from July 2018.